Stocks Health care ACXP
NASDAQ · Health careAcurx Pharmaceuticals, Inc. (ACXP)
It posted a net loss of $7.5M. At June 30, 2026 it held $10.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Acurx Pharmaceuticals, Inc.
- Net worth
- Acurx Pharmaceuticals, Inc. has a market value (market cap) of $5.5M at the latest share price, and shareholders' equity of $8.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $6.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Acurx Pharmaceuticals, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Acurx Pharmaceuticals, Inc. does
Acurx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACXP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8M | -$5.32 | n/a |
| 2024 | n/a | -$14.1M | -$17.45 | n/a |
| 2023 | n/a | -$14.6M | -$23.07 | n/a |
| 2022 | n/a | -$12.1M | -$22.46 | n/a |
| 2021 | n/a | -$12.7M | -$29.89 | n/a |
| 2021 | n/a | -$4.6M | -$14.84 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Acurx Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026IPO registration S-1
- September 1, 2026
- September 1, 2026Additional proxy material DEFA14A
- September 1, 2026Proxy statement DEF 14A
- August 13, 2026
- May 11, 2026
- May 4, 2026IPO registration S-1
- May 4, 2026IPO registration S-1
- April 16, 2026
- March 12, 2026
Insider trades
What the people running Acurx Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about ACXP
What does Acurx Pharmaceuticals, Inc. do?
Acurx Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ACXP. Its shares trade on NASDAQ under the ticker ACXP.
What is Acurx Pharmaceuticals, Inc.'s net worth?
Acurx Pharmaceuticals, Inc. has a market value (market cap) of $5.5M at the latest share price, and shareholders' equity of $8.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Acurx Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $7.5M.
When did Acurx Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 8, 2026.
When is Acurx Pharmaceuticals, Inc.'s next earnings report?
Acurx Pharmaceuticals, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare ACXP with
Follow ACXP
Get an email when Acurx Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Acurx Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.